🧬Anthropic Acquires Drug Discovery Startup Coefficient Bio for $400M
Anthropic Acquires Drug Discovery Startup Coefficient Bio f…
TL;DR
Anthropic acquired Coefficient Bio, an eight-month-old startup built by former Evozyne, Genentech, and Prescient Design computational biologists, for roughly $…
Anthropic acquired Coefficient Bio, an eight-month-old startup built by former Evozyne, Genentech, and Prescient Design computational biologists, for roughly $400 million in stock. The deal marks one of the first direct bets by a frontier AI lab on in-house drug discovery capability.
Key Points
Coefficient Bio founded by Evozyne and Genentech alumni
All-stock deal valued around $400M
Anthropic signals direct move into biologics design
Why It Matters
Frontier labs acquiring domain-specific science teams suggests the next commercial frontier for LLM infrastructure is regulated, data-scarce verticals like drug design.
Frequently Asked Questions
Why does this matter?
Frontier labs acquiring domain-specific science teams suggests the next commercial frontier for LLM infrastructure is regulated, data-scarce verticals like drug design.
What happened?
Anthropic acquired Coefficient Bio, an eight-month-old startup built by former Evozyne, Genentech, and Prescient Design computational biologists, for roughly $…
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.